Top Story

VB-111 plus bevacizumab confers positive interim results in recurrent glioblastoma

March 26, 2015

Interim results from an ongoing phase 2 study demonstrated that patients with recurrent glioblastoma who received VB-111 alone and subsequently with bevacizumab achieved significantly improved OS compared with patients who received VB-111 followed by bevacizumab monotherapy, according to a press release from the drug’s manufacturer.

Researchers evaluated VB-111 (VBL Therapeutics) — the first agent based on transcriptional targeting of tumor endothelium to be assessed in a clinical trial — in 46 patients with recurrent glioblastoma. Patients received VB-111 alone until disease progression. Twenty-two patients were then treated with bevacizumab (Avastin, Genentech) monotherapy. Of the 24 remaining patients, 23 chose to receive further treatment with VB-111 plus bevacizumab. One patient remains stable on VB-111 alone at 424 days.

In the Journals

Metronomic temozolomide extends PFS, OS in EGFR-amplified glioblastoma

March 16, 2015
Patients with epidermal growth factor receptor-amplified and -overexpressing glioblastomas demonstrated a significant benefit from metronomic temozolomide-based…
Richard Pazdur, MD FDA News

FDA approves Unituxin for pediatric patients with high-risk neuroblastoma

March 10, 2015
The FDA today announced the approval of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, according to a press release from the…
Breaking News

Oraya receives CE mark extension for IRay to treat choroidal metastases

March 3, 2015
The Oraya IRay radiotherapy system received a CE mark extension for the treatment of choroidal metastases, expanding on prior approval for treatment of wet age-related…
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Industry News

VB-111 plus bevacizumab confers positive interim results in recurrent glioblastoma

March 26, 2015
Interim results from an ongoing phase 2 study demonstrated that patients with recurrent glioblastoma who received VB-111 alone and subsequently with…
In the Journals

Metronomic temozolomide extends PFS, OS in EGFR-amplified glioblastoma

March 16, 2015
Patients with epidermal growth factor receptor-amplified and -overexpressing glioblastomas demonstrated a significant benefit from metronomic…
Richard Pazdur, MD FDA News

FDA approves Unituxin for pediatric patients with high-risk neuroblastoma

March 10, 2015
The FDA today announced the approval of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, according to a press…
Breaking News

Oraya receives CE mark extension for IRay to treat choroidal metastases

March 3, 2015
The Oraya IRay radiotherapy system received a CE mark extension for the treatment of choroidal metastases, expanding on prior approval for treatment…
In the Journals

Chest CT imaging may safely be omitted from neuroblastoma surveillance for pediatric patients

February 27, 2015
Neuroblastoma progression or recurrence in the chest is rare among children and usually can be detected with non-CT imaging modalities or through the…
FDA NewsDrug Pipeline

FDA grants breakthrough therapy designation to Rintega for EGFRvIII-positive glioblastoma

February 23, 2015
 The FDA today granted breakthrough therapy designation to rindopepimut for the treatment of adults with epidermal growth factor receptor…
FDA NewsDrug Pipeline

FDA grants orphan drug status to BXQ-350 for treatment of glioblastoma multiforme

February 16, 2015
The FDA granted orphan drug designation to BXQ-350, an agent in development for treatment of glioblastoma multiforme.BXQ-350 (Bexion Pharmaceuticals)…
Meeting News CoveragePerspective

Optune plus temozolomide extended survival in glioblastoma

February 6, 2015
Use of the noninvasive regional therapy Optune with temozolomide chemotherapy significantly extended OS and PFS in patients with newly diagnosed…
FDA NewsDrug Pipeline

FDA grants orphan drug status to SL-701 for glioma treatment

January 30, 2015
The FDA today granted orphan drug designation to SL-701 for the treatment of glioma, according to a press release from the drug’s…
In the Journals

Bevacizumab-induced hypertension associated with improved OS, PFS in glioblastoma

January 27, 2015
Patients with recurrent glioblastoma who experienced bevacizumab-induced hypertension demonstrated prolonged OS and PFS, according to study…
More Headlines »
morganatic-roan